Treatment.Com International Inc. (TRUE.CN)
CAD 0.41
(-1.22%)
CAD 0.41
(-1.22%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.32 Million CAD | 39.41% |
| 2022 | -3.84 Million CAD | 72.41% |
| 2021 | -13.91 Million CAD | -378.63% |
| 2020 | -2.9 Million CAD | -332.54% |
| 2019 | -672.36 Thousand CAD | -859.42% |
| 2018 | -70.08 Thousand CAD | 27.39% |
| 2017 | -96.52 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1.72 Million CAD | -92.25% |
| 2024 Q1 | -904.03 Thousand CAD | -6.15% |
| 2023 Q2 | -269.12 Thousand CAD | 29.41% |
| 2023 Q4 | -851.64 Thousand CAD | -0.96% |
| 2023 Q3 | -843.56 Thousand CAD | -213.44% |
| 2023 FY | -2.32 Million CAD | 39.41% |
| 2023 Q1 | -381.22 Thousand CAD | 55.07% |
| 2022 Q4 | -848.52 Thousand CAD | -143.06% |
| 2022 Q3 | -349.09 Thousand CAD | 41.6% |
| 2022 Q2 | -597.79 Thousand CAD | 70.32% |
| 2022 FY | -3.84 Million CAD | 72.41% |
| 2022 Q1 | -2.01 Million CAD | 65.98% |
| 2021 Q4 | -5.92 Million CAD | -27.47% |
| 2021 FY | -13.91 Million CAD | -378.63% |
| 2021 Q3 | -4.64 Million CAD | -106.14% |
| 2021 Q2 | -2.25 Million CAD | -109.4% |
| 2021 Q1 | -1.07 Million CAD | 15.62% |
| 2020 Q4 | -1.27 Million CAD | -101.1% |
| 2020 FY | -2.9 Million CAD | -332.54% |
| 2020 Q3 | -634.21 Thousand CAD | 15.73% |
| 2020 Q2 | -752.61 Thousand CAD | -205.88% |
| 2020 Q1 | -246.04 Thousand CAD | 56.55% |
| 2019 Q4 | -566.25 Thousand CAD | -1313.27% |
| 2019 FY | -672.36 Thousand CAD | -859.42% |
| 2019 Q3 | -40.06 Thousand CAD | 0.0% |
| 2018 FY | -70.08 Thousand CAD | 27.39% |
| 2017 FY | -96.52 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AI/ML Innovations Inc. | -1.66 Million CAD | -39.765% |
| Diagnamed Holdings Corp. | -1.17 Million CAD | -97.589% |
| Pangenomic Health Inc. | -2.71 Million CAD | 14.192% |
| nDatalyze Corp. | -316.56 Thousand CAD | -635.068% |
| Unidoc Health Corp. | -2.2 Million CAD | -5.739% |